Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serelaxin for Portal Hypertension in Cirrhosis
NCT02669875Phase 2Completed
- Sponsor
- University of Edinburgh
- Start
- Oct 2017
- Primary completion
- Aug 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in Portal Hypertension (PH) comparing Serelaxin Arm with Placebo Arm (2 arms). Primary endpoint: Hepatic Venous Pressure Gradient at 2 hours. Started Oct 2017; status: completed.
02
Drugs
serelaxin
03
Conditions
Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT02669875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02669875.